Biomarkers in Alzheimer’s Disease is focused on biomarker identification and development in patients with Alzheimer’s Disease. This report focuses on the Alzheimer’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Alzheimer’s Disease, Biomarkers in Alzheimer’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.
Experts interviewed in this report include:
- Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, PharmaTherapeutics, Pfizer Worldwide R&D
- Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University
- Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
Insight Pharma Reports also put together a table of clinical trial information and pipeline data from multiple databases related to Alzheimer’s Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.